Clareo Health | Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation
Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
FORUM Pharmaceuticals Inc
Age
21–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female ages aged ≥21 and ≤75 years
Genotyped positive for a FTD-GRN mutation, and aware of it
Prodromal to moderate FTD-GRN
Resides in a stable living situation, living at home, senior residential setting, or an institutional setting without the need for continuous (ie, 24-hour) nursing care
Proficiency (oral and written) in the language in which study-related documents, including the ICF and standardized tests, will be administered
Able to swallow capsules
Be in good general health, willing and able to comply with the protocol requirements, and expected to complete the study as designed (in the judgment of the investigator)
You may not be if
Clinically significant abnormalities on physical examination, medical history, ECG, vital signs, laboratory values, or unstable medical or psychiatric illness
Females who are pregnant, breastfeeding, or planning to become pregnant during the study
